Mixture Sciences, Inc. Co-authors Recent Article in Cancer Research Describing the Integration of Combinatorial Chemistry and Bioinformatics for the Development of Tumor Vaccines.

Mixture Sciences, Inc., of San Diego, California, in collaboration with researchers at the Ludwig Institute for Cancer Research, the Torrey Pines Institute for Molecular Studies and the National Cancer Institute report on the utility of mixture-based peptide combinatorial libraries and biometrical data analysis for the identification of peptides recognized by T lymphocytes in the April 1, 2002 issue of Cancer Research (62, 2058-2063). Mixture-based combinatorial libraries and biometrical data analysis are integral components of Mixture Sciences ligand discovery platform. The results reported in the article illustrate the power of mixture-based peptide combinatorial libraries, specifically positional scanning synthetic combinatorial libraries (PS-SCL), in conjunction with biometrical data analysis for the identification and optimization of tumor associated antigens. The identification of effective and potent antigens is an important step forward in the design of effective cancer vaccines.

Mixture Sciences, Inc. Co-authors Recent Article in Cancer Research Describing the Integration of Combinatorial Chemistry and Bioinformatics for the Development of Tumor Vaccines.

Mixture Sciences, Inc., of San Diego, California, in collaboration with researchers at the Ludwig Institute for Cancer Research, the Torrey Pines Institute for Molecular Studies and the National Cancer Institute report on the utility of mixture-based peptide combinatorial libraries and biometrical data analysis for the identification of peptides recognized by T lymphocytes in the April 1, 2002 issue of Cancer Research (62, 2058-2063). Mixture-based combinatorial libraries and biometrical data analysis are integral components of Mixture Sciences ligand discovery platform. The results reported in the article illustrate the power of mixture-based peptide combinatorial libraries, specifically positional scanning synthetic combinatorial libraries (PS-SCL), in conjunction with biometrical data analysis for the identification and optimization of tumor associated antigens. The identification of effective and potent antigens is an important step forward in the design of effective cancer vaccines.

Mixture Sciences, Inc., www.mixturesciences.com, a privately-held biotechnology company, specializes in biomedical research and drug discovery. We use a combination of proprietary and in-licensed technologies for the discovery of therapeutic and diagnostic candidates for the treatment of HIV/AIDS, cancer, diabetes, multiple sclerosis, and infectious diseases, including Lyme Disease. Our technologies have been validated and used by members of the academic and corporate community over the past decade.
Our success comes from being a worldwide leader in the use of mixture-based chemical libraries. Our unique position allows us to provide our collaborators exceptional technologies and expertise. Mixture Sciences, Inc. is committed to developing, improving, patenting and in-licensing new technologies in order to provide our collaborators with the most cost efficient methods for identifying ligands.